hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease

Withdrawn before enrolling · Not applicable

Conditions studied: Chronic Kidney Disease, Vitamin D Deficiency

In brief

The human immune system produces a protein called hCAP18 (also known as LL-37 or cathelicidin). This protein is believed to help the body to fight infections. Studies suggest that vitamin D may important in the production of hCAP18. This study is designed to test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks. After this, follow-up levels will be measured.

Key facts

Study ID

NCT01026363

Run by

Massachusetts General Hospital

People needed

0

Starts

2009-12-01

Expected to finish

2014-12-01

Last updated by the study team

2015-09-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80
• Chronic Kidney Disease stage 3-4 (estimated glomerular filtration rate 15-60 ml/min)

You may not qualify if…

• 6 month history of hypercalcemia, hyperphosphatemia, or nephrolithiasis
• use of active vitamin D analog within 30 days
• functioning renal transplant
• Symptoms of active infection
• Granulomatous disorders

Where it is running

• Massachusetts Institute of Technology — Cambridge, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.